Answers are grounded in this paper and cite their sources.
In phase 3 clinical trials for ceftobiprole treatment of complicated skin and skin structure infections, 1,219 gram-positive and 276 gram-negative aerobic baseline pathogens were identified. Ceftobiprole inhibited all staphylococcal isolates, including methicillin-resistant strains, at MICs of </=4 mug/ml. Against Enterobacteriaceae and Pseudomonas aeruginosa isolates, the potency of ceftobiprole was similar to that of cefepime.
No takes yet. Share an insight, caveat, or question.
Amsler et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: